Ep. 141: Devon Krantz, Molecule

Molecule is an open market based platform that incentivizes the development and co-creation of pharmaceutical IP. Molecule's CEO, Devon Krantz, discusses the dire state of pharmacological R&D and its cost—literally and figuratively—to patients. Molecule, on the other hand, encourages a patient-centric approach to pharma. How? Devon puts it this way: "We are focusing more on bio-techs, on smaller research labs, on academia. [What we] want to incentivize is for researchers, scientists, and academics to take their IP, and maybe it's in an underfunded area, and put it onto the Blockchain, into an open market, which then enables other people to buy into the market and freely grow that market. We're democratizing access to cures." Devon elaborates on the innovative and complex 'why & how' during the rest of the conversation.

You can listen to Ep. 141: Devon Krantz, Molecule online on Radio and Podcast. Open the player on this page to stream the available audio.

Ep. 141: Devon Krantz, Molecule is an episode from CX Network by Seth Adler.

This episode is 26:21 long.

This episode was published on Dec 25, 2019.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from CX Network when more episodes are available from the podcast feed.